The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
 
Jacob Drobnyk Soumerai
No Relationships to Disclose
 
John M. Pagel
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics
 
Deepa Jagadeesh
No Relationships to Disclose
 
Huda S. Salman
No Relationships to Disclose
 
Vaishalee Padgaonkar Kenkre
Research Funding - Abbott Laboratories; Celgene; Gilead Sciences; Infinity Pharmaceuticals; MEI Pharma; Roche/Genentech; Seagen
 
Adam Steven Asch
No Relationships to Disclose
 
Anastasios Stathis
Honoraria - Amgen
Research Funding - Celgene; MEI Pharma; Merck; Pfizer
 
Nishitha M. Reddy
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Gilead Sciences
 
Alexia Iasonos
No Relationships to Disclose
 
Richard Ghalie
Employment - MEI Pharma
Leadership - Viracta Therapeutics
 
Andrew David Zelenetz
Stock and Other Ownership Interests - Adaptive Biotechnologies
Honoraria - Kirin Pharmaceuticals; Medscape; Takeda
Consulting or Advisory Role - Acerta Pharma; Alissa Pharma; Alphasights; Amgen; Celgene; Genentech/Roche; Gilead Sciences; Hospira; Pharmacyclics
Research Funding - BeiGene; Bristol-Myers Squibb; Genentech/Roche; Gilead Sciences; MEI Pharma
Travel, Accommodations, Expenses - Gilead Sciences; Kirin Pharmaceuticals; Medscape; Takeda
Other Relationship - Boehringer Ingelheim; Quintiles